https://www.selleckchem.com/pr....oducts/deruxtecan.ht
Chemotherapy use was associated with an improved 5-year survival (HR = 1.63, 95% CI 1.28-2.07). Upon subgroup analysis, this association was lost in patients 70years and those with a RS ≤ 11, while patients ≤ 70 with a RS of 12-25 treated with chemotherapy had an absolute 5-year survival advantage of 3.0% (HR = 1.91, 95% CI 1.42-2.57). Clinicians should be cautious when considering omission of adjuvant chemotherapy in patients ≤ 70years, with HR+, HER2-, N1 tumors and a RS 12-25, at least until the results of the anticipated RxP
Like
Comment
Share
